STELLAR BANCORP DL -01 (C9N0) - Net Assets
Based on the latest financial reports, STELLAR BANCORP DL -01 (C9N0) has net assets worth €1.67 Billion EUR (≈ $1.95 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€10.89 Billion ≈ $12.73 Billion USD) and total liabilities (€9.22 Billion ≈ $10.78 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check C9N0 strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.67 Billion |
| % of Total Assets | 15.32% |
| Annual Growth Rate | 19.57% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 27.34 |
STELLAR BANCORP DL -01 - Net Assets Trend (2021–2025)
This chart illustrates how STELLAR BANCORP DL -01's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see STELLAR BANCORP DL -01 stock valuation.
Annual Net Assets for STELLAR BANCORP DL -01 (2021–2025)
The table below shows the annual net assets of STELLAR BANCORP DL -01 from 2021 to 2025. Also explore how fast is STELLAR BANCORP DL -01 growing its equity to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €1.67 Billion ≈ $1.95 Billion |
+3.78% |
| 2024-12-31 | €1.61 Billion ≈ $1.88 Billion |
+5.71% |
| 2023-12-31 | €1.52 Billion ≈ $1.78 Billion |
+9.97% |
| 2022-12-31 | €1.38 Billion ≈ $1.62 Billion |
+69.41% |
| 2021-12-31 | €816.47 Million ≈ $954.54 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to STELLAR BANCORP DL -01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 112.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €566.22 Million | 33.93% |
| Other Components | €1.10 Billion | 66.07% |
| Total Equity | €1.67 Billion | 100.00% |
STELLAR BANCORP DL -01 Competitors by Market Cap
The table below lists competitors of STELLAR BANCORP DL -01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Xiamen ITG Group Corp Ltd
SHG:600755
|
$1.75 Billion |
|
Ningxia Jiaze Renewables Corp
SHG:601619
|
$1.75 Billion |
|
Austevoll Seafood ASA
OL:AUSS
|
$1.75 Billion |
|
Vukile Property Fund Ltd
JSE:VKE
|
$1.75 Billion |
|
S&T Bancorp Inc
NASDAQ:STBA
|
$1.75 Billion |
|
NCC AB (publ)
ST:NCC-B
|
$1.75 Billion |
|
4DMEDICAL Ltd
AU:4DX
|
$1.75 Billion |
|
Jamf Holding
NASDAQ:JAMF
|
$1.75 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in STELLAR BANCORP DL -01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,607,860,000 to 1,668,654,000, a change of 60,794,000 (3.8%).
- Net income of 102,872,000 contributed positively to equity growth.
- Dividend payments of 29,296,000 reduced retained earnings.
- Share repurchases of 73,352,000 reduced equity.
- Other factors increased equity by 60,570,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €102.87 Million | +6.16% |
| Dividends Paid | €29.30 Million | -1.76% |
| Share Repurchases | €73.35 Million | -4.4% |
| Other Changes | €60.57 Million | +3.63% |
| Total Change | €- | 3.78% |
Book Value vs Market Value Analysis
This analysis compares STELLAR BANCORP DL -01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.05x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €33.34 | €34.40 | x |
| 2022-12-31 | €26.12 | €34.40 | x |
| 2023-12-31 | €28.54 | €34.40 | x |
| 2024-12-31 | €30.09 | €34.40 | x |
| 2025-12-31 | €32.78 | €34.40 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently STELLAR BANCORP DL -01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.16%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 24.30%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 6.48x
- Recent ROE (6.16%) is below the historical average (7.12%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 9.99% | 34.39% | 0.03x | 8.70x | €-93.80K |
| 2022 | 3.72% | 16.63% | 0.03x | 7.88x | €-86.89 Million |
| 2023 | 8.58% | 28.29% | 0.04x | 7.00x | €-21.60 Million |
| 2024 | 7.15% | 26.68% | 0.04x | 6.78x | €-45.78 Million |
| 2025 | 6.16% | 24.30% | 0.04x | 6.48x | €-63.99 Million |
Industry Comparison
This section compares STELLAR BANCORP DL -01's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| STELLAR BANCORP DL -01 (C9N0) | €1.67 Billion | 9.99% | 5.53x | $1.75 Billion |
| Covestro AG (1COV) | $5.25 Billion | 10.51% | 1.19x | $11.10 Billion |
| CENTESSA PHARMACEUTICALS (260) | $401.55 Million | -58.71% | 0.44x | $5.35 Billion |
| 2invest AG (2INV) | $82.98 Million | 26.70% | 0.01x | $70.69 Million |
| COINSHARES I. LS-000247 (3TW) | $393.95 Million | 33.24% | 14.29x | $472.53 Million |
| Adaptimmune Therapeutics plc (473A) | $166.14 Million | -43.08% | 0.41x | $42.94 Million |
| KINGMAN MINERALS LTD. (47A) | $1.44 Million | -21.74% | 0.28x | $178.38K |
| GENOR BIOPHARMA DL-00002 (67N0) | $1.19 Billion | -56.64% | 0.22x | $93.97 Million |
| BENO Holding AG (BENH) | $30.09 Million | 13.51% | 2.23x | $75.57K |
| Biotest Aktiengesellschaft (BIO) | $380.40 Million | -16.67% | 1.90x | $976.15 Million |
| Biotest Aktiengesellschaft (BIO3) | $110.79 Million | 17.87% | 2.36x | $656.94 Million |
About STELLAR BANCORP DL -01
As of July 1, 2026, Stellar Bancorp, Inc. was taken private. Stellar Bancorp, Inc. operates as the bank holding company that provides a range of commercial banking products and services primarily to small and medium-sized businesses, professionals, and individual customers. It provides deposit products that include checking accounts, commercial accounts, money market accounts, savings accounts, a… Read more